105
Participants
Start Date
June 24, 2021
Primary Completion Date
April 28, 2025
Study Completion Date
April 28, 2025
Nemolizumab
Participants will receive subcutaneous (SC) injection of 10, 20 or 30 milligrams (mg) nemolizumab, every 4 weeks (Q4W) for 52 weeks with a loading dose of 20, 40 or 60 mg at Day 1 based on the body weight.
Nemolizumab
Participants will receive SC injection of 5, 10 or 15 mg nemolizumab, Q4W for 52 weeks with a loading dose of 10, 20 or 30 mg at Day 1 based on the body weight.
Galderma Investigational Site #6147, Budapest
Galderma Investigational Site #6218, Hellerup
Galderma Investigational Site #5531, Szeged
Galderma Investigational Site #8560, West Bloomfield
Galderma Investigational Site #8636, Fountain Valley
Galderma Investigational Site #9937, San Diego
Galderma Investigational Site #9930, Vista
Galderma Investigational Site #9929, Coral Gables
Galderma Investigational Site #8142, Indianapolis
Galderma Investigational Site #8092, Louisville
Galderma Investigational Site #8155, Troy
Galderma Investigational Site #8242, Brooklyn
Galderma Investigational Site #9938, New York
Galderma Investigational Site #8206, Norman
Galderma Investigational Site #8255, Philadelphia
Galderma Investigational Site #9931, Beaumont
Galderma Investigational Site #78218-3128, San Antonio
Galderma Investigational Site #5570, Lodz
Galderma Investigational Site #6237, Ostrowiec Świętokrzyski
Galderma Investigational Site #5495, Rzeszów
Galderma Investigational Site #6262, Warsaw
Galderma Investigational Site #6261, Wroclaw
Galderma Investigational Site #5896, Esplugues de Llobregat
Lead Sponsor
Galderma R&D
INDUSTRY